SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...
Recursion is using AI and machine learning to accelerate drug research and development. The stock has been under pressure amid an uncertain near-term financial outlook. Several clinical updates from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback